No AccessJournal of UrologyAdult Urology1 Jan 2018

Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation

    View All Author Information


    We evaluated the therapeutic success rate, changes in quality of life and safety of sacral neuromodulation 5 years after InterStim™ implantation. Included in study were subjects with bothersome symptoms of overactive bladder, including urinary urge incontinence and/or urgency-frequency, in whom at least 1 anticholinergic medication failed and 1 medication had not been tried.

    Materials and Methods:

    Therapeutic success was defined as a urinary urge incontinence or urgency-frequency response of 50% or greater improvement in average leaks or voids per day, or return to normal voiding, defined as fewer than 8 voids per day. Quality of life was evaluated by ICIQ-OABqol (International Consultation on Incontinence Modular Questionnaire). Safety was evaluated through adverse events.


    Of the 340 subjects who completed the test stimulation 272 had an implant, of whom 91% were female. Mean age was 57 years. At baseline 202 subjects with urinary urge incontinence had a mean ± SD of 3.1 ± 2.7 leaks per day and 189 with urgency-frequency had a mean of 12.6 ± 4.5 voids per day. The 5-year therapeutic success rate was 67% (95% CI 60–74) using modified completers analysis and 82% (95% CI 76–88) using completers analysis. Subjects with urinary urge incontinence had a mean reduction from baseline of 2.0 ± 2.2 leaks per day and subjects with urgency-frequency had a mean reduction of 5.4 ± 4.3 voids per day (each completers analysis p <0.0001). Subjects showed improvement in all ICIQ-OABqol measures (p <0.0001). The most common device related adverse events were an undesirable change in stimulation in 60 of the 272 subjects (22%), implant site pain in 40 (15%) and therapeutic product ineffectiveness in 36 (13%).


    This multicenter study shows that sacral neuromodulation had sustained efficacy and quality of life improvements, and an acceptable safety profile through 5 years in subjects with overactive bladder.


    • 1 : The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int2009; 104: 352. Google Scholar
    • 2 : Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol2015; 193: 1572. LinkGoogle Scholar
    • 3 : The management of overactive bladder syndrome: a review of the European Association of Urology Guidelines. Clin Pract2013; 10: 593. Google Scholar
    • 4 : Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int2013; 111: 106. Google Scholar
    • 5 : Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study. J Urol2013; 189: 2194. LinkGoogle Scholar
    • 6 : Five-year follow-up after sacral neuromodulation: single center experience. Neuromodulation2007; 10: 363. Google Scholar
    • 7 : Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int2014; 113: 789. Google Scholar
    • 8 : Neuromodulation for overactive bladder symptoms in women utilizing either motor or sensory/motor provocation with a minimum nine-year follow-up. Neuromodulation2015; 18: 517. Google Scholar
    • 9 : Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol2007; 51: 1357. Google Scholar
    • 10 : Sacral nerve stimulation for voiding dysfunction: one institution’s 11-year experience. Neurourol Urodyn2007; 26: 19. Google Scholar
    • 11 : Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn2015; 34: 224. Google Scholar
    • 12 : Three-year follow-up results of a prospective, multicenter study in overactive bladder subjects treated with sacral neuromodulation. Urology2016; 94: 57. Google Scholar
    • 13 : Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Neurourol Urodyn2016; 35: 246. Google Scholar
    • 14 : Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res2002; 11: 563. Google Scholar
    • 15 : Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol1998; 51: 677. Google Scholar
    • 16 : The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. Br J Urol1996; 77: 805. Google Scholar
    • 17 : Manual for the Beck Depression Inventory II. San Antonio, Texas: The Psychological Corp1996. Google Scholar
    • 18 : OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA2016; 316: 1366. Google Scholar
    • 19 Noblett K, Berg KC, Kan F et al: Baseline symptom severity and therapeutic success in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Unpublished data. Google Scholar
    • 20 : Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol2007; 178: 2029. LinkGoogle Scholar
    • 21 : Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients. Neurourol Urodyn2017; 36: 1136. Google Scholar
    • 22 : Sacral neuromodulation and botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol2015; 33: 1109. Google Scholar
    • 23 : Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J2015; 9: 242. Google Scholar